PaulDenisLegerMD

PubMed

• 17 citations
  Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race.
  Paul Leger, Sanika Chirwa, Megan Turner, Danielle M. Richardson, Paxton Baker
  Pharmacogenetics and Genomics. 2016-10-01
• 59 citations
  Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomis...
  Mina C. Hosseinipour, Gregory P. Bisson, Sachiko Miyahara, Xin Sun, Agnes Moses
  Lancet. 2016-03-19
• 39 citations
  Clinical features of acquired resistance to anti–PD-1 therapy in advanced melanoma
  Daniel Y. Wang, Zeynep Eroglu, Alpaslan Özgün, Paul Leger, Shilin Zhao
  Cancer Immunology Research. 2017-04-10

Journal Articles

• Race/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuation  
  1) Leger P., Chirva S., Nwogu J., Tuner M., Richardson D., Baker P., Leonard M., Erdem H., Olson L., Haas D., Pharmacogent Genomics, 1/28/2018
• A Case Report of Severe Type B Lactic Acidosis Following First Dose of Nivolumab in a VHL-Mutated Metastatic Renal Cell Carcinoma.  
  2) Nakajima E., Leger P., Mayer I., Neuss M., Chism D., Rathmell K, Kidney Cancer, 7/2017
• Clinical features of acquired resistance in anti-PD-1 therapy  
  3) Wang D., Zeynep E., Ozgun A., Leger P., Zhao S., Ye F., Luke J., Joseph R., Sosman J., Johnson D., Buchbinder E, Cancer Immunology Research, 5/2017
• Pharmacogenetics of Efavirenz Discontinuation for Reported Central Nervous System Symptoms Appears to Differ by Race  
  4) Leger P., Chirwa S., Turner M., Richardson D., Baker P., Leonard M., Erdem H., Olson L., Haas D.., Pharmacogenetics and Genomics, 10/2016
• Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multi-country open-label randomi...  
  1) Hosseinipour M., Bisson G., Miyahara S. Leger P., Gupta A., The Lancet, 3/2016
• Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa  
  5) Sinxadi P., Leger P., McIleron H., Smith P., Dave J., Levitt N., Maartens G., Haas D.., Br J Clin Pharmacol, 7/2015
• Multiple Genetic Variants Predict Steady-State Nevirapine Clearance in HIV-infected Cambodians  
  7) Bertrand J., Chou M., Richardson D., Verstuyft C., Leger P., Mentre F., Taburet A., Haas D., Pharmacogenet Genomics., 12/2012
• Virologic, Clinical and Immunologic Responses following Failure of First-line Antiretroviral Therapy in Haiti  
  2) Charles M., Leger P., Severe P., Guiteau C., Apollon A., Gulick R., Johnson W., Pape J., Fitzgerald D, Journal of the International AIDS Society, 6/2012
• 5-Year Survival of Patients with AIDS Receiving Antiretroviral Therapy in Haiti  
  6) Leger P., Charles M., Severe P., Riviere C., Pape J., Fitzgerald D, New England Journal of Medicine, 8/2009
• Antiretroviral Therapy in a Thousand Patients with AIDS in Haiti  
  12) Severe P., Leger P.,Charles M., Noel F., Bonhomme J., Bois G.,George E., Kenel-Pierre S.,Wright P., Gulick R., Johnson W., Pape J.,Fitzgerald D, New England Journal of Medicine, 12/2005
• Join now to see all